Ricevi le ultime notizie sulle azioni Bio-Path Holdings con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di BPTH

Ultime notizie per

Bio-Path Holdings

BIO-PATH HOLDINGS INC by Bio-Path Holdings, Inc.

Bio-Path Holdings Inc

Bio-Path Holdings (BPTH) Previsione

Notizie

Utili

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Comments

Bio-Path Holdings Notizie sulle azioni

Notizie

Ultime notizie per

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO